Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

REGENXBIO
1701 Pennsylvania Ave., NW, Suite 900
Washington, DC 20006
Phone: 202-785-7438
http://www.regenxbio.com/

REGENXBIO Inc. is the leading next-generation AAV gene therapy company, developing a new class of personalized therapies based on its proprietary NAV(R) Technology platform for a range of severe diseases with serious unmet needs. NAV Technology includes novel AAV vectors AAV7, AAV8, AAV9, and AAVrh10. REGENXBIO has enabled leading global partners including Baxter Healthcare, Fondazione Telethon, Audentes Therapeutics, Lysogene, Esteve, AveXis, AAVLife and Voyager Therapeutics to use its NAV Technology. In addition, together with Fidelity Biosciences, REGENXBIO formed Dimension Therapeutics, a company focused on the development and commercialization of NAV-based gene therapies for liver-directed rare diseases.

Key Contact
Name
Ken Mills
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
01/21/15 $30,000,000 Series C Brookside Capital
Deerfield Management Company, L.P.
FoxKiser
Venrock
05/20/15 $70,500,000 Series D Brookside Capital
Cormorant Asset Management
Deerfield Management Company, L.P.
Foresite Capital
Janus Capital
Jennison Associates
Perceptive Advisors
QVT Financial
RTW Investments
Tourbillon Global Ventures
Venrock
Vivo Ventures


Featured Reading